Somatic gene therapy for cardiovascular disease Recent advances

E Barr; J M Leiden

doi:10.1016/1050-1738(94)90010-8

Somatic gene therapy for cardiovascular disease Recent advances

Trends Cardiovasc Med. 1994 Mar-Apr;4(2):57-63. doi: 10.1016/1050-1738(94)90010-8.

Authors

E Barr¹, J M Leiden

Affiliation

¹ Department of Medicine, University of Chicago, Chicago, IL 60637, USA.

PMID: 21244896
DOI: 10.1016/1050-1738(94)90010-8

Abstract

The recent development of several novel approaches for in vivo gene transfer into the coronary arteries and myocardium has led to new possibilities for the treatment of both acquired and inherited cardiovascular diseases. This review summarizes the current state of the art of in vivo gene transfer into the heart and coronary arteries with particular emphasis on antisense oligonucleotide-mediated suppression of gene expression in vascular smooth muscle cells, liposome-mediated gene transfer into the vasculature, and percutaneous transluminal gene transfer (PTGT) into the heart with the use of replication-defective adenoviruses.